Hans Schambye

Outlook DigitalOcean Nginx WordPress.org Google Font API Mobile Friendly Google Tag Manager Google Analytics

galectin modulators galectin3 inhibitors fibrosis treatment loxl2 inflammation oncology ipf liver fibrosis myelofibrosis biotechnology: pharmaceutical preparations health care biotechnology research cancer treatment liver diseases small molecules biotechnology clinical-stage therapeutic platform acute myeloid leukemia aml enl-yeats inhibitor flt3 inhibitor galectin-3 oral small molecule non-small cell lung cancer melanoma treatment head & neck cancer decompensated cirrhosis drug discovery drug development synergistic therapies clinical trials patient quality of life oncology pipeline research innovation biopharmaceutical pharmaceutical development biotech executives fibrosis-focused pioneering research biomedical research pipeline development investigator-initiated trial standard of care therapies multi-target approach therapeutic efficacy molecular biology biomedical applications drug candidates targeted therapies research grants scientific conferences scientific publications fibrosis biomarkers disease pathways clinical endpoints safety & efficacy patent estate galecto inc. hospital & health care health wellness & fitness